Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

otsuka america pharmaceutical, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify (aripiprazole) oral tablets, orally-disintegrating tablets, and oral solution are indicated for the treatment of: - schizophrenia - acute treatment of manic and mixed episodes associated with bipolar i disorder - adjunctive treatment of major depressive disorder - irritability associated with autistic disorder - treatment of tourette's disorder abilify injection is indicated for the treatment of: - agitation associated with schizophrenia or bipolar mania abilify is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including abilify, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhea

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

major pharmaceuticals - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - aripiprazole oral tablets are indicated for the treatment of: aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions ( 6.2) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including abilify, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/. risk summary neonates exposed to antipsychotic drugs, including aripiprazole, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

exelan pharmaceuticals, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - aripiprazole oral tablets are indicated for the treatment of: • schizophrenia [see clinical studies ( 14.1 )] additional pediatric use information is approved for otsuka america pharmaceutical, inc.'s abilify ® (aripiprazole) product. however, due to otsuka america pharmaceutical, inc.'s marketing exclusivity rights, this drug product is not labeled with that information. aripiprazole tablets are contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . teratogenic effects pregnancy category c: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to aripiprazole during pregnancy. for more information contact the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. risk summary neonates exposed t

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - aripiprazole is indicated for the treatment of: •  schizophrenia •  irritability associated with autistic disorder •  treatment of tourette’s disorder additional pediatric use information is approved for otsuka america pharmaceutical, inc.’s abilify® (aripiprazole) product. however, due to otsuka america pharmaceutical, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions  (6.2)]. pregnancy exposure registry   there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including aripiprazole, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-progr

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

alembic pharmaceuticals limited - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - aripiprazole is indicated for the treatment of: •schizophrenia [see clinical studies (14.1)] additional pediatric use information is approved for otsuka america pharmaceutical, inc.’s abilify® (aripiprazole) product. however, due to otsuka america pharmaceutical, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)]. teratogenic effects pregnancy category c: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to aripiprazole during pregnancy. for more information contact the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. risk summary neonates exposed to antipsychotic drugs (includi

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; hyprolose; croscarmellose sodium; magnesium stearate; iron oxide red - tevaripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - aripiprazole, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; hyprolose; croscarmellose sodium; magnesium stearate - tevaripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; iron oxide yellow; hyprolose; croscarmellose sodium; magnesium stearate - tevaripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - aripiprazole, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; iron oxide red; hyprolose; croscarmellose sodium; magnesium stearate - tevaripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - aripiprazole, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; iron oxide yellow; hyprolose; croscarmellose sodium; magnesium stearate - tevaripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.